Meeting
2019 Genitourinary Cancers Symposium
A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.
Authors
David Johnson Einstein
Beth-Israel Deaconess Medcl Ctr, Boston, MA
David Johnson Einstein , Atish Dipankar Choudhury , Philip James Saylor , Lillian Werner , Mark G. Erlander , Maya Ridinger , Glenn Bubley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03414034
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS336)
DOI
10.1200/JCO.2019.37.7_suppl.TPS336
Abstract #
TPS336
Poster Bd #
N12
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: David Johnson Einstein
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: David Johnson Einstein
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel P. Petrylak
Poster
2022 ASCO Genitourinary Cancers Symposium
DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study.
First Author: Manish R. Patel